Drug Trial Radar · NCT06858865
A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282
Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Jul 12, 2025
Primary completion
Aug 14, 2025
Study completion Aug 14, 2025
Sponsor
- Lead sponsor
- Addpharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228A in healthy subjects.
Conditions
- Primary Hypercholesterolaemia
Interventions
AD-228ADrug
AD-228A Oral Tablet
AD-2281 and AD-2282Drug
AD-2281 Oral Tablet + AD-2282 Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum concentration of drug in plasma (Cmax)Time frame: pre-dose to 72 hours
- Area under the plasma concentration-time curve during dosing interval (AUCt)Time frame: pre-dose to 72 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
H+ Yangji Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.